GRI Bio (GRI) Research & Development (2020 - 2026)
GRI Bio (GRI) posted quarterly Research & Development of $361000.0 for Q1 2026, down 77.99% year-over-year from $1.6 million in Q1 2025, and down 77.87% quarter-over-quarter from $1.6 million in Q4 2025.
GRI Bio (GRI) Research & Development (2020 - 2026) Analysis & Trends
GRI Bio's Research & Development history runs 7 years deep, the most recent figure standing at $361000.0 for Q1 2026.
- In Q1 2026, Research & Development fell 77.99% year-over-year to $361000.0; the TTM figure through Mar 2026 stood at $5.6 million (up 23.98% YoY), while the FY2025 annual figure was $6.8 million, up 80.97% from the prior year.
- Research & Development for Q1 2026 stood at $361000.0, down from $1.6 million in the prior quarter.
- The five-year high for Research & Development was $1.9 million in Q2 2025, with the low at $59000.0 in Q2 2022.
- The 5-year median for Research & Development is $933000.0 (2024), against an average of $929823.5.
- The sharpest annual moves came in 2022 and 2023: Research & Development slumped 96.95% in 2022, then surged 1787.3% in 2023.
- GRI Bio's Research & Development stood at $61000.0 in 2022, then soared by 1614.75% to $1.0 million in 2023, then fell by 13.29% to $907000.0 in 2024, then jumped by 79.82% to $1.6 million in 2025, then plunged by 77.87% to $361000.0 in 2026.
- Business Quant data shows GRI's Research & Development at $361000.0 in Q1 2026, $1.6 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - | 407,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 361,000.00 |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 1.88 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 907,000.00 |
| Sep 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 877,000.00 |
| Mar 31, 2024 | 933,000.00 |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 880,000.00 |
| Mar 31, 2023 | 116,000.00 |
| Dec 31, 2022 | 61,000.00 |
| Sep 30, 2022 | 63,000.00 |
| Jun 30, 2022 | 59,000.00 |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | 2.00 Mn |
| Sep 30, 2021 | 215,000.00 |
| Jun 30, 2021 | 1.20 Mn |